Katie Tuckwell

Katie Tuckwell joined Sonoma Biotherapeutics in May 2021 as Senior Director of Clinical Development, with over 10 years’ experience working on multiple clinical trials in autoimmune indications spanning Phase 1-4 development.

Most recently, Tuckwell was a Principal Clinical Scientist in the gRED Early Clinical Development group at Genentech where she was the Clinical Subteam Leader for Phase 1 and 2 studies in rheumatoid arthritis, lupus and systemic sclerosis as well as a Phase 3 study in COVID-19. Prior to this, she worked in the Late-Stage Clinical Development group at Roche, UK, where she worked on rheumatoid arthritis and giant cell arteritis, and had a central role in the development and approval of Actemra as the first treatment for giant cell arteritis.

Tuckwell received her B.Sc. in Biochemistry from the University of Reading, UK, and her Ph.D. in Biochemistry from the University of Bristol, UK. Before joining Roche, she worked in medical communications and diagnostic development, including at DNA Electronics (an Imperial College, London spin-out company).